申请人:Merck Patent Gesellschaft mit beschrankter Haftung
公开号:US04733011A1
公开(公告)日:1988-03-22
Compounds of the formula ##STR1## wherein A is C--C single bond, --CH.sub.2 --, --CH(CH.sub.3)--, --C(CH.sub.3).sub.2 --, --CH.sub.2 --CH.sub.2 --, CH(CH.sub.3)CH.sub.2 --, --C(CH.sub.3).sub.2 CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 -- or --CH.sub.2 O--; R.sup.1a and R.sup.1 each independently is hydrogen or a protective group which can be cleaved by solvolysis or by hydrogenolysis; R.sup.2 is H or alkyl of 1 to 3 C atoms; R.sup.3 is alkyl of 3 to 5 C atoms, phenyl or phenyl which is monosubstituted to trisubstituted by F, Cl, OH, OCH.sub.3, OC.sub.2 H.sub.5, CF.sub.3 or alkyl of 1 to 3 C atoms, or, when A is not --CH.sub.2 O--, can also be pyridyl, thienyl, naphthyl or alkoxy of 1 to 4 C atoms; indicates a bond in the .beta.-position and wavy line ( ) means that the bond can be in the .alpha.- or .beta.-position, are valuable intermediates for the stereospecific preparation of 13-thiaprostaglandin derivatives. The latter are prepared by U.V. irradiation of the former to first prepare the corresponding 2-oxa-3-OH-6-alkylthio-7-OH-1,5-bicyclo(3.3.0)octane derivative, which is then exposed to a Wittig reaction and, optionally, hydrogenation or oxidation inter alia to prepare members of the F.sub.1 -, F.sub.2 -, E.sub.1 - and E.sub.2 series.
公式为##STR1##的化合物,其中A为C--C单键,--CH.sub.2--,--CH(CH.sub.3)--,--C(CH.sub.3).sub.2--,--CH.sub.2--CH.sub.2--,CH(CH.sub.3)CH.sub.2--,--C(CH.sub.3).sub.2CH.sub.2--,--CH.sub.2--CH.sub.2--CH.sub.2--或--CH.sub.2O--; R.sup.1a和R.sup.1分别独立地为氢或可通过溶剂解离或氢解离裂解的保护基团; R.sup.2为H或1至3个碳原子的烷基; R.sup.3为3至5个碳原子的烷基,苯基或经F,Cl,OH,OCH.sub.3,OC.sub.2H.sub.5,CF.sub.3或1至3个碳原子的烷基单取代至三取代的苯基,或者当A不是--CH.sub.2O--时也可以是吡啶基,噻吩基,萘基或1至4个碳原子的烷氧基; 指示β位上的键,波浪线()表示该键可以在α位或β位,对于特定构造的13-硫代前列腺素衍生物的立体特异性制备是有价值的中间体。后者通过对前者进行紫外辐射首先制备相应的2-氧杂-3-OH-6-烷基硫-7-OH-1,5-双环(3.3.0)辛烷衍生物,然后暴露于威蒂格反应和,可选地,氢化或氧化等反应,制备F.sub.1-, F.sub.2-, E.sub.1-和E.sub.2系列的成员。